About: Frédéric Triebel

Facets (new session)
Description
Metadata
Settings
- Rule:
- Inverse Functional Properties:
- "Same As":

About: Frédéric Triebel Goto Sponge NotDistinct Permalink

An Entity of Type : wikidata:Q901, within Data Space : dbpedia.demo.openlinksw.com associated with source document(s)
QRcode icon

http://dbpedia.demo.openlinksw.com/c/5KvHuqDRQ9

Frédéric Triebel (born 20 November 1954) is a French immunologist who is best known for his 1990 discovery of the LAG3 immune control mechanism. Triebel worked through the 1990s in a collaboration between Institut Gustave Roussy and Merck Serono to establish LAG-3's mechanism of action in T cells and dendritic cells. In 2001 he founded Immutep SA, a biotech company, to develop the therapeutic potential of LAG3. In 2014 this company was acquired by Prima BioMed, where Triebel remains Chief Scientific and Medical Officer.

Attributes	Values
rdf:type	Thing foaf:Person person dul:NaturalPerson Eukaryote Person Human Animal animal eukaryote scientist species schema:Person Scientist
rdfs:label	Frédéric Triebel (en) Frédéric Triebel (fr)
rdfs:comment	Frédéric Triebel (born 20 November 1954) is a French immunologist who is best known for his 1990 discovery of the LAG3 immune control mechanism. Triebel worked through the 1990s in a collaboration between Institut Gustave Roussy and Merck Serono to establish LAG-3's mechanism of action in T cells and dendritic cells. In 2001 he founded Immutep SA, a biotech company, to develop the therapeutic potential of LAG3. In 2014 this company was acquired by Prima BioMed, where Triebel remains Chief Scientific and Medical Officer. (en) Frédéric Triebel, né le 20 novembre 1954, est un immunologiste français qui est surtout connu pour sa découverte en 1990 du mécanisme de contrôle immunitaire du LAG3. Triebel a travaillé pendant les années 1990 dans le cadre d'une collaboration entre l'Institut Gustave-Roussy et Merck Serono pour établir le mécanisme d'action du LAG-3 dans les cellules T et les cellules dendritiques. En 2001, il fonde Immutep SA, une société de biotechnologie, pour développer le potentiel thérapeutique du LAG3. En 2014, cette société a été acquise par Prima BioMed, où Triebel reste directeur scientifique et médical. (fr)
foaf:name	Frédéric Triebel (en)
name	Frédéric Triebel (en)
birth place	Cameroon Douala
birth place	Cameroon Douala
birth date	1954-11-20 (xsd:date)
dct:subject	1954 births Living people French immunologists People from Douala
Wikipage page ID	46533824 (xsd:integer)
Wikipage revision ID	1085861499 (xsd:integer)
Link from a Wikipage to another Wikipage	Cameroon Merck Serono Dendritic cells Antigen University of Paris-Sud Institut Gustave Roussy Institut Universitaire de France 1954 births Living people Ligand French immunologists France People from Douala French Institute of Health and Medical Research MHC class II Dimer (chemistry) Prima BioMed Recombinant DNA Hematology LAG3 T cells Douala Pierre and Marie Curie University Immunologist Immunology Immutep Immunogenetics MHC Class II Poitiers University
sameAs	Frédéric Triebel Frédéric Triebel Frédéric Triebel Frédéric Triebel Frédéric Triebel Frédéric Triebel
workplaces	Institut Gustave Roussy, University of Paris XI, Immutep, Prima BioMed (en)
dbp:wikiPageUsesTemplate	dbt:About dbt:Authority_control dbt:BLP_sources dbt:Reflist dbt:Short_description dbt:Birth_date_and_age dbt:Infobox_scientist
birth date	1954-11-20 (xsd:date)
fields	Immunology, Translational medicine (en)
known for	Discovering LAG-3 (en)
nationality	France
has abstract	Frédéric Triebel (born 20 November 1954) is a French immunologist who is best known for his 1990 discovery of the LAG3 immune control mechanism. Triebel worked through the 1990s in a collaboration between Institut Gustave Roussy and Merck Serono to establish LAG-3's mechanism of action in T cells and dendritic cells. In 2001 he founded Immutep SA, a biotech company, to develop the therapeutic potential of LAG3. In 2014 this company was acquired by Prima BioMed, where Triebel remains Chief Scientific and Medical Officer. (en) Frédéric Triebel, né le 20 novembre 1954, est un immunologiste français qui est surtout connu pour sa découverte en 1990 du mécanisme de contrôle immunitaire du LAG3. Triebel a travaillé pendant les années 1990 dans le cadre d'une collaboration entre l'Institut Gustave-Roussy et Merck Serono pour établir le mécanisme d'action du LAG-3 dans les cellules T et les cellules dendritiques. En 2001, il fonde Immutep SA, une société de biotechnologie, pour développer le potentiel thérapeutique du LAG3. En 2014, cette société a été acquise par Prima BioMed, où Triebel reste directeur scientifique et médical. (fr)
institution	University of Paris-Sud Institut Gustave Roussy Prima BioMed Immutep
gold:hypernym	Immunologist
prov:wasDerivedFrom	wikipedia-en:Frédéric_Triebel?oldid=1085861499&ns=0
page length (characters) of wiki page	10219 (xsd:nonNegativeInteger)
academic discipline	Immunology
known for	LAG3
nationality	France
foaf:isPrimaryTopicOf	wikipedia-en:Frédéric_Triebel
is Link from a Wikipage to another Wikipage of	Institut Gustave Roussy GSK2831781 Frederic Triebel Eftilagimod alpha Triebel (disambiguation) Immutep Lymphocyte-activation gene 3
is Wikipage redirect of	Frederic Triebel
is Wikipage disambiguates of	Triebel (disambiguation)

Faceted Search & Find service v1.17_git147 as of Sep 06 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 08.03.3331 as of Sep 2 2024, on Linux (x86_64-generic-linux-glibc212), Single-Server Edition (378 GB total memory, 63 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software